Suppr超能文献

针对 SARS-CoV-2 变体和未来大流行的疫苗。

Vaccines against SARS-CoV-2 variants and future pandemics.

机构信息

Department of Biology, College of Life Science and Industry, Sunchon National University (SCNU), Suncheon, South Korea.

College of Veterinary Medicine and Interdisciplinary Graduate Program in Advanced Convergence Technology and Science, Jeju National University, Jeju, South Korea.

出版信息

Expert Rev Vaccines. 2022 Oct;21(10):1363-1376. doi: 10.1080/14760584.2022.2110075. Epub 2022 Aug 12.

Abstract

INTRODUCTION

Vaccination continues to be the most effective method for controlling COVID-19 infectious diseases. Nonetheless, SARS-CoV-2 variants continue to evolve and emerge, resulting in significant public concerns worldwide, even after more than 2 years since the COVID-19 pandemic. It is important to better understand how different COVID-19 vaccine platforms work, why SARS-CoV-2 variants continue to emerge, and what options for improving COVID-19 vaccines can be considered to fight against SARS-CoV-2 variants and future pandemics.

AREA COVERED

Here, we reviewed the innate immune sensors in the recognition of SARS-CoV-2 virus, innate and adaptive immunity including neutralizing antibodies by different COVID-19 vaccines. Efficacy comparison of the several COVID-19 vaccine platforms approved for use in humans, concerns about SARS-CoV-2 variants and breakthrough infections, and the options for developing future COIVD-19 vaccines were also covered.

EXPERT OPINION

Owing to the continuous emergence of novel pathogens and the reemergence of variants, safer and more effective new vaccines are needed. This review also aims to provide the knowledge basis for the development of next-generation COVID-19 and pan-coronavirus vaccines to provide cross-protection against new SARS-CoV-2 variants and future coronavirus pandemics.

摘要

简介

接种疫苗仍然是控制 COVID-19 传染病最有效的方法。尽管如此,SARS-CoV-2 变体仍在不断进化和出现,这导致全球范围内公众对此高度关注,即使自 COVID-19 大流行以来已经过去了 2 年多。了解不同的 COVID-19 疫苗平台如何发挥作用、为什么 SARS-CoV-2 变体仍在不断出现以及可以考虑哪些改进 COVID-19 疫苗的选择来对抗 SARS-CoV-2 变体和未来的大流行至关重要。

涵盖领域

在这里,我们回顾了 SARS-CoV-2 病毒识别中的先天免疫传感器、不同 COVID-19 疫苗引起的先天和适应性免疫(包括中和抗体)。我们还涵盖了已批准用于人类的几种 COVID-19 疫苗平台的功效比较、对 SARS-CoV-2 变体和突破性感染的关注,以及开发未来 COVID-19 疫苗的选择。

专家意见

由于新病原体的不断出现和变体的再次出现,需要更安全、更有效的新型疫苗。本综述还旨在为下一代 COVID-19 和泛冠状病毒疫苗的开发提供知识基础,以针对新的 SARS-CoV-2 变体和未来的冠状病毒大流行提供交叉保护。

相似文献

1
Vaccines against SARS-CoV-2 variants and future pandemics.
Expert Rev Vaccines. 2022 Oct;21(10):1363-1376. doi: 10.1080/14760584.2022.2110075. Epub 2022 Aug 12.
3
COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.
Front Cell Infect Microbiol. 2021 Sep 10;11:690621. doi: 10.3389/fcimb.2021.690621. eCollection 2021.
5
SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies.
Int Rev Immunol. 2023;42(6):393-414. doi: 10.1080/08830185.2022.2079642. Epub 2022 May 28.
6
Heterologous immunity induced by 1 generation COVID-19 vaccines and its role in developing a pan-coronavirus vaccine.
Front Immunol. 2022 Aug 15;13:952229. doi: 10.3389/fimmu.2022.952229. eCollection 2022.
7
Current scenario of COVID-19 vaccinations and immune response along with antibody titer in vaccinated inhabitants of different countries.
Int Immunopharmacol. 2021 Oct;99:108050. doi: 10.1016/j.intimp.2021.108050. Epub 2021 Aug 6.
8
COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants.
Cell. 2021 Sep 30;184(20):5077-5081. doi: 10.1016/j.cell.2021.09.010. Epub 2021 Sep 17.
10
Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
mSystems. 2023 Apr 27;8(2):e0092722. doi: 10.1128/msystems.00927-22. Epub 2023 Mar 2.

引用本文的文献

4
Antigen Delivery Platforms for Next-Generation Coronavirus Vaccines.
Vaccines (Basel). 2024 Dec 31;13(1):30. doi: 10.3390/vaccines13010030.
6
Incidence and management of the main serious adverse events reported after COVID-19 vaccination.
Pharmacol Res Perspect. 2024 Jun;12(3):e1224. doi: 10.1002/prp2.1224.
7
Weight loss treatment for COVID-19 in patients with NCDs: a pilot prospective clinical trial.
Sci Rep. 2024 May 14;14(1):10979. doi: 10.1038/s41598-024-61703-1.
8
Ecological comparison of six countries in two waves of COVID-19.
Front Public Health. 2024 Feb 28;12:1277457. doi: 10.3389/fpubh.2024.1277457. eCollection 2024.
10
A cardiotoxicity-eliminated ACE2 variant as a pan-inhibitor against coronavirus cell invasion.
Mol Ther. 2024 Jan 3;32(1):218-226. doi: 10.1016/j.ymthe.2023.11.019. Epub 2023 Nov 15.

本文引用的文献

1
Risk of and duration of protection from SARS-CoV-2 reinfection assessed with real-world data.
PLoS One. 2023 Mar 21;18(3):e0280584. doi: 10.1371/journal.pone.0280584. eCollection 2023.
2
Humoral and cellular immune memory to four COVID-19 vaccines.
Cell. 2022 Jul 7;185(14):2434-2451.e17. doi: 10.1016/j.cell.2022.05.022. Epub 2022 May 27.
3
Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine.
N Engl J Med. 2022 Jun 2;386(22):2084-2096. doi: 10.1056/NEJMoa2201300. Epub 2022 May 4.
6
Effectiveness of COVID-19 vaccine (Covaxin) against breakthrough SARS-CoV-2 infection in India.
Hum Vaccin Immunother. 2022 Dec 31;18(1):2034456. doi: 10.1080/21645515.2022.2034456. Epub 2022 Mar 23.
7
Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa.
Science. 2022 May 6;376(6593):eabn4947. doi: 10.1126/science.abn4947.
8
9
SARS-CoV-2-Specific Vaccine Candidates; the Contribution of Structural Vaccinology.
Vaccines (Basel). 2022 Feb 3;10(2):236. doi: 10.3390/vaccines10020236.
10
Evaluation of the Immune Response Induced by CoronaVac 28-Day Schedule Vaccination in a Healthy Population Group.
Front Immunol. 2022 Jan 31;12:766278. doi: 10.3389/fimmu.2021.766278. eCollection 2021.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验